Skip to main content

FDA advisory panel says widely used decongestant considered ineffective

An advisory panel for the U.S. Food and Drug Administration decided Tuesday an ingredient widely used in nasal decongestants doesn't work any better than a placebo pill.

A Food and Drug Administration (FDA) advisory panel declared Tuesday an ingredient widely used in over-the-counter cold and allergy medications doesn't work. 

All 16 members of the Nonprescription Drugs Advisory Committee (NDAC) unanimously agreed that oral phenylephrine, found in common versions of Sudafed, Mucinex, Vicks, Allegra and Dayquil, isn't effective in offering relief from nasal congestion. 

Not only did the panel declare the drug ineffective, but it also warned that, at a higher dose, it can also cause someone's blood pressure to reach dangerous levels, according to a report from The Associated Press. 

"Poor efficacy really is a safety issue," Dr. Steve Clement, associate professor of Medical Education at the University of Virginia School of Medicine and a panel member, said Tuesday. 

ASPARTAME SWEETENER USED IN DIET COKE, SOME CHEWING GUM, MAY BE DEEMED 'POSSIBLY CARCINOGENIC': REPORT

Jennifer Schwartzott, a patient representative on the panel, also noted Tuesday that patients not only require but "deserve medications that treat their symptoms safely and effectively." She doesn't "believe that this medication does that" and that it should have been removed from the market "a long time ago."

The FDA has been evaluating data with regard to orally administered phenylephrine (PE) since the Nonprescription Drugs Advisory Committee challenged its effectiveness during a meeting in December 2007, according to the FDA's briefing document.

HEALTH OFFICIALS CLASSIFY ASPARTAME 'POSSIBLY CARCINOGENIC' DESPITE 'LIMITED EVIDENCE' IT CAUSES CANCER

Numerous studies have been conducted since that time to reevaluate "the scientific support for use of oral PE as a nasal decongestant." 

The committee held a two-day meeting this week after researchers petitioned the FDA to remove phenylephrine products due to the fact that several studies showed that it was no better than placebo pills in patients with cold and allergy congestion, according to The Associated Press. 

If the FDA finds phenylephrine ineffective, drugmakers could be forced to pull certain drugs from store shelves in the U.S. Consumers might also have to seek behind-the-counter pills, nasal sprays or drops. Those products are not under review.

GET FOX BUSINESS ON THE GO BY CLICKING HERE

According to the National Institutes of Health, pseudoephedrine, a nasal decongestant, is sold behind the counter nationwide because it can be used to make methamphetamine.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.